Payers and Partnerships: The Top Three Reimbursement Questions for Biotech Companies
This article was originally published in RPM Report
CEOs of smaller biotech companies are often on the road trying to raise money or look at licensing deals. The ability to answer key reimbursement questions gives them a competitive advantage over their counterparts.
You may also be interested in...
The new statutory requirement that Medicare drug plans cover all drugs in protected drug classes includes a hint of possible flexibility for interested stakeholders - the designated groups could be expanded or subtracted, though only through a formal regulatory process
Despite hopes that research on the comparative effectiveness of health services could both improve health care quality and reduce spending, the creation of an expanded federal program remains stuck in the examination phase
A statutory requirement that Medicare Part D drug plans cover "all or substantially all" drugs in six classes stands a good chance of making it into the Senate Finance Committee's upcoming Medicare physician payment package